B-cell lymphoma overview

Jump to navigation Jump to search

B-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

B-cell lymphoma overview On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of B-cell lymphoma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on B-cell lymphoma overview

CDC on B-cell lymphoma overview

B-cell lymphoma overview in the news

Blogs on B-cell lymphoma overview

Directions to Hospitals Treating B-cell lymphoma

Risk calculators and risk factors for B-cell lymphoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Shivali Marketkar, M.B.B.S. [2]

Overview

B-cell lymphomas make up most (about 85%) of the non-Hodgkin lymphomas (NHL) in the United States. It develops more frequently in immunocompromised individuals (such as those with AIDS.)

Classification

B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkins lymphomas. They are typically divided into low and high grade, typically corresponding to indolent (slow-growing) lymphomas and aggressive lymphomas, respectively. . The most commonly used classification system is the WHO classification, a convergence of more than one, older classification systems.

Most common

Five account for nearly three out of four patients with non-Hodgkin lymphoma:[1]

Rare

The remaining forms are much less common:[1]

Others

Additionally, some researchers separate out lymphomas that appear result from other immune system disorders, such as AIDS-related lymphoma. Classic Hodgkin's lymphoma and nodular lymphocyte predominant Hodgkin's lymphoma are now considered forms of B-cell lymphoma.[2]

Pathophysiology


Genetics

Chromosomal translocations involving the immunoglobulin heavy locus (IGH@) is a classic cytogenetic abnormality for many B-cell lymphomas, including follicular lymphoma, mantle cell lymphoma and Burkitt's lymphoma. In these cases, The immunoglobulin heavy locus forms a fusion protein with another protein that has pro-proliferative or anti-apoptotic abilities. The enhancer element of the immunoglobulin heavy locus, which normally functions to make B cells produce massive production of antibodies, now induces massive transcription of the fusion protein, resulting in excessive pro-proliferative or anti-apoptotic effects on the B cells containing the fusion protein. In Burkitt's lymphoma and mantle cell lymphoma, the other protein in the fusion is c-myc (on chromosome 8) and cyclin D1[3] (on chromosome 11), respectively, which gives the fusion protein pro-proliferative ability. In follicular lymphoma, the fused protein is Bcl-2 (on chromosome 18), which gives the fusion protein anti-apoptotic abilities.

Microscopic Pathology

Shown below is a microscopic image of Hodgkins Lymphoma which is a type of B cell lymphoma.Lymph node FNA specimen(Field's stain) The micrograph shows a mixture of cells commonly seen in Hodgkins lymphoma:

  • Eosinophils
  • Reed Sternberg cells
  • Plasma cells
  • Histiocytes



Treatment

Medical Therapy

  • Treatment includes radiation and chemotherapy.
  • Early-stage indolent B-cell lymphomas can often be treated with radiation alone, with long-term non-recurrence.
  • Early-stage aggressive disease is treated with chemotherapy and often radiation, with a 70-90% cure rate.[4]
  • Late-stage indolent lymphomas are sometimes left untreated and monitored until they progress.
  • Late-stage aggressive disease is treated with chemotherapy, with cure rates of over 70%.[4]

References

  1. 1.0 1.1 "The Lymphomas" (PDF). The Leukemia & Lymphoma Society. May 2006. pp. p. 12. Retrieved 2008-04-07.
  2. "HMDS: Hodgkin's Lymphoma". Archived from the original on 4 March 2009. Retrieved 2009-02-01.
  3. Li JY, Gaillard F, Moreau A; et al. (1999). "Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization". Am. J. Pathol. 154 (5): 1449–52. doi:10.1016/S0002-9440(10)65399-0. PMC 1866594. PMID 10329598. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 Merck Manual home edition, Non-Hodgkin Lymphomas


Template:WikiDoc Sources